Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia

Neuropharmacology

Volumn 91, Issue , 2015, Pages 43-56

  Hsu, Chao Yu ^a   Hung, Ching Sui ^b   Chang, Hung Ming ^c   Liao, Wen Chieh ^d,e   Ho, Shih Chun ^e   Ho, Ying Jui ^e  

^a Tungs' Taichung MetroHabor Hospital   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Ceftriaxone; Dementia; Glutamate transporter 1; Glutamatergic hyperactivity; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CEFTRIAXONE; PROCAINE PENICILLIN; VESICULAR GLUTAMATE TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; NEUROPROTECTIVE AGENT; SLC1A2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; HIPPOCAMPAL CA1 REGION; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; SUBTHALAMIC NUCLEUS; T-MAZE TEST; WORKING MEMORY; ANIMAL; BRAIN; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; MAZE TEST; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PSYCHOLOGY; RECOGNITION; WISTAR RAT;

ANIMALS; ASTROCYTES; BRAIN; CEFTRIAXONE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EXCITATORY AMINO ACID TRANSPORTER 2; MALE; MAZE LEARNING; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY);

EID: 84919629579     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.11.023     Document Type: Article

References (128)

1. D. Aarsland, K. Andersen, J.P. Larsen, A. Lolk, H. Nielsen, and P. Kragh-Sorensen Risk of dementia in Parkinson's disease: a community-based, prospective study Neurology 56 2001 730 736
2. D. Aarsland, J. Zaccai, and C. Brayne A systematic review of prevalence studies of dementia in Parkinson's disease Mov. Disord. 20 2005 1255 1263
3. R.L. Albin, and J.T. Greenamyre Alternative excitotoxic hypotheses Neurology 42 1992 733 738
4. S. Ando, S. Kobayashi, H. Waki, K. Kon, F. Fukui, T. Tadenuma, M. Iwamoto, Y. Takeda, N. Izumiyama, K. Watanabe, and H. Nakamura Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine J. Neurosci. Res. 70 2002 519 527
5. M.T. Armentero, R. Fancellu, G. Nappi, P. Bramanti, and F. Blandini Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease Neurobiol. Dis. 22 2006 1 9
6. C. Bancher, H. Braak, P. Fischer, and K.A. Jellinger Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients Neurosci. Lett. 162 1993 179 182
7. O. Bar-Peled, H. Ben-Hur, A. Biegon, Y. Groner, S. Dewhurst, A. Furuta, and J.D. Rothstein Distribution of glutamate transporter subtypes during human brain development J. Neurochem. 69 1997 2571 2580
8. C. Barcia, A. Sanchez Bahillo, E. Fernandez-Villalba, V. Bautista, Y.P.M. Poza, A. Fernandez-Barreiro, E.C. Hirsch, and M.T. Herrero Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure Glia 46 2004 402 409
9. J. Barnes, L. Boubert, J. Harris, A. Lee, and A.S. David Reality monitoring and visual hallucinations in Parkinson's disease Neuropsychologia 41 2003 565 574
10. G. Battaglia, C.L. Busceti, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice J. Neurosci. 24 2004 828 835
11. M.I. Bellissimo, I. Kouzmine, M.M. Ferro, B.H. de Oliveira, N.S. Canteras, and C. Da Cunha Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats? Neurobiol. Learn. Mem. 82 2004 150 158
12. A. Benazzouz, S. Breit, A. Koudsie, P. Pollak, P. Krack, and A.L. Benabid Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease Mov. Disord. 17 Suppl. 3 2002 S145 S149
13. H. Bergman, T. Wichmann, B. Karmon, and M.R. DeLong The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism J. Neurophysiol. 72 1994 507 520
14. F. Blandini, M. Garcia-Osuna, and J.T. Greenamyre Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats Eur. J. Neurosci. 9 1997 1407 1413
15. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni Functional changes of the basal ganglia circuitry in Parkinson's disease Prog. Neurobiol. 62 2000 63 88
16. F. Blandini, R.H. Porter, and J.T. Greenamyre Glutamate and Parkinson's disease Mol. Neurobiol. 12 1996 73 94
17. H. Braak, E. Braak, D. Yilmazer, R.A. de Vos, E.N. Jansen, and J. Bohl Pattern of brain destruction in Parkinson's and Alzheimer's diseases J. Neural. Transm. 103 1996 455 490
18. H. Braak, U. Rub, E.N. Jansen Steur, K. Del Tredici, and R.A. de Vos Cognitive status correlates with neuropathologic stage in Parkinson disease Neurology 64 2005 1404 1410
19. H. Braak, U. Rub, C. Schultz, and K. Del Tredici Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases J. Alzheimers. Dis. 9 2006 35 44
20. R. Braga, I. Kouzmine, N.S. Canteras, and C. Da Cunha Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats Exp. Neurol. 192 2005 134 141
21. N.J. Broadbent, L.R. Squire, and R.E. Clark Spatial memory, recognition memory, and the hippocampus Proc. Natl. Acad. Sci. U. S. A. 101 2004 14515 14520
22. R.G. Brown, and C.D. Marsden How common is dementia in Parkinson's disease? Lancet 2 1984 1262 1265
23. R. Camicioli, M.M. Moore, A. Kinney, E. Corbridge, K. Glassberg, and J.A. Kaye Parkinson's disease is associated with hippocampal atrophy Mov. Disord. 18 2003 784 790
24. C. Capitelli, A. Sereniki, M.M. Lima, A.B. Reksidler, S. Tufik, and M.A. Vital Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats Eur. J. Pharmacol. 594 2008 101 108
25. D. Centonze, P. Gubellini, S. Rossi, B. Picconi, A. Pisani, G. Bernardi, P. Calabresi, and C. Baunez Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism Neuroscience 133 2005 831 840
26. C. Cepeda, and M.S. Levine Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum Dev. Neurosci. 20 1998 1 18
27. R. Chihab, J. Oillet, C. Bossenmeyer, and J.L. Daval Glutamate triggers cell death specifically in mature central neurons through a necrotic process Mol. Genet. Metab. 63 1998 142 147
28. K. Chu, S.T. Lee, D.I. Sinn, S.Y. Ko, E.H. Kim, J.M. Kim, S.J. Kim, D.K. Park, K.H. Jung, E.C. Song, S.K. Lee, M. Kim, and J.K. Roh Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) Upregulation Stroke 38 2007 177 182
29. A. Churchyard, and A.J. Lees The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease Neurology 49 1997 1570 1576
30. C. Da Cunha, M.E. Angelucci, N.S. Canteras, S. Wonnacott, and R.N. Takahashi The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities Cell. Mol. Neurobiol. 22 2002 227 237
31. C. Da Cunha, M.S. Gevaerd, M.A. Vital, E. Miyoshi, R. Andreatini, R. Silveira, R.N. Takahashi, and N.S. Canteras Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia Behav. Brain. Res. 124 2001 9 18
32. C. Da Cunha, S. Wietzikoski, E.C. Wietzikoski, E. Miyoshi, M.M. Ferro, J.A. Anselmo-Franci, and N.S. Canteras Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system Neurobiol. Learn. Mem. 79 2003 236 242
33. N.C. Danbolt Glutamate uptake Prog. Neurobiol. 65 2001 1 105
34. A.G. Dervan, C.K. Meshul, M. Beales, G.J. McBean, C. Moore, S. Totterdell, A.K. Snyder, and G.E. Meredith Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease Exp. Neurol. 190 2004 145 156
35. A. Ennaceur, and J. Delacour A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data Behav. Brain. Res. 31 1988 47 59
36. A. Ennaceur, N. Neave, and J.P. Aggleton Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix Exp. Brain Res. 113 1997 509 519
37. M.M. Ferro, M.I. Bellissimo, J.A. Anselmo-Franci, M.E. Angellucci, N.S. Canteras, and C. Da Cunha Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations J. Neurosci. Meth. 148 2005 78 87
38. J.W. Francis, J. Von Visger, G.J. Markelonis, and T.H. Oh Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum Neurotoxicol. Teratol. 17 1995 7 12
39. A. Furuta, J.D. Rothstein, and L.J. Martin Glutamate transporter protein subtypes are expressed differentially during rat CNS development J. Neurosci. 17 1997 8363 8375
40. M.S. Gevaerd, R.N. Takahashi, R. Silveira, and C. Da Cunha Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats Brain Res. Bull. 55 2001 101 106
41. H. Hall, S. Reyes, N. Landeck, C. Bye, G. Leanza, K. Double, L. Thompson, G. Halliday, and D. Kirik Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease Brain 137 2014 2493 2508
42. O.K. Hassani, M. Mouroux, and J. Feger Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus Neuroscience 72 1996 105 115
43. M.A. Hediger, and T.C. Welbourne Introduction: glutamate transport, metabolism, and physiological responses Am. J. Physiol. 277 1999 F477 F480
44. E. Hedlund The protective effects of beta-lactam antibiotics in motor neuron disorders Exp. Neurol. 231 2011 14 18
45. M.P. Hill, P. Ravenscroft, E. Bezard, A.R. Crossman, J.M. Brotchie, A. Michel, R. Grimee, and H. Klitgaard Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease J. Parmacol. Exp. Ther. 310 2004 386 394
46. E. Hirsch, A.M. Graybiel, and Y.A. Agid Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334 1988 345 348
47. S.C. Ho, C.C. Hsu, C.R. Pawlak, M.A. Tikhonova, T.J. Lai, T.G. Amstislavskaya, and Y.J. Ho Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model Behav. Brain Res. 268 2014 177 184
48. Y.J. Ho, K.H. Chen, M.Y. Tai, and Y.F. Tsai MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors Pharmacol. Biochem. Behav. 77 2004 641 646
49. Y.J. Ho, J. Eichendorff, and R.K. Schwarting Individual response profiles of male Wistar rats in animal models for anxiety and depression Behav. Brain Res. 136 2002 1 12
50. Y.J. Ho, S.C. Ho, C.R. Pawlak, and K.Y. Yeh Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia Behav. Brain Res. 219 2011 280 290
51. Y.J. Ho, L.S. Hsu, C.F. Wang, W.Y. Hsu, T.J. Lai, C.C. Hsu, and Y.F. Tsai Behavioral effects of d-cycloserine in rats: the role of anxiety level Brain Res. 1043 2005 179 185
52. J.R. Hollerman, and A.A. Grace Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol Brain Res. 590 1992 291 299
53. S.K. Hota, K. Barhwal, K. Ray, S.B. Singh, and G. Ilavazhagan Ceftriaxone rescues hippocampal neurons from excitotoxicity and enhances memory retrieval in chronic hypobaric hypoxia Neurobiol. Learn. Mem. 89 2008 522 532
54. M.H. Hsieh, S.L. Gu, S.C. Ho, C.R. Pawlak, C.L. Lin, Y.J. Ho, T.J. Lai, and F.Y. Wu Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model Behav. Brain Res. 229 2012 41 47
55. M.H. Hsieh, S.C. Ho, K.Y. Yeh, C.R. Pawlak, H.M. Chang, Y.J. Ho, T.J. Lai, and F.Y. Wu Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model Pharmacol. Biochem. Behav. 102 2012 64 71
56. S.S. Huang, J. He, D.M. Zhao, X.Y. Xu, H.P. Tan, and H. Li Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions Cell. Mol. Neurobiol. 30 2010 1107 1115
57. M.R. Hunsaker, J.A. Thorup, T. Welch, and R.P. Kesner The role of CA3 and CA1 in the acquisition of an object-trace-place paired-associate task Behav. Nurosci. 120 2006 1252 1256
58. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 106 2003 518 526
59. J. Jankovic Parkinson's disease: clinical features and diagnosis J. Neurol. Neurosurg. Psychiatry 79 2008 368 376
60. K.A. Jellinger, and W. Paulus Clinico-pathological correlations in Parkinson's disease Clin. Neurol. Neurosurg. 94 Suppl. l 1992 S86 S88
61. M.V. Johnston Excitotoxicity in neonatal hypoxia Ment. Retard. Dev. Disabil. Res. Rev. 7 2001 229 234
62. Y. Kanai, and M.A. Hediger The glutamate and neutral amino acid transporter family: physiological and pharmacological implications Eur. J. Pharmacol. 479 2003 237 247
63. C.J. Karwoski, H.K. Lu, and E.A. Newman Spatial buffering of light-evoked potassium increases by retinal Muller (glial) cells Science 244 1989 578 580
64. J. Kassa, M. Koupilova, and J. Vachek Long-term effects of low-level sarin inhalation exposure on the spatial memory of rats in a T-maze Acta Medica (Hradec Kralove) 44 2001 93 96
65. K. Kim, S.G. Lee, T.P. Kegelman, Z.Z. Su, S.K. Das, R. Dash, S. Dasgupta, P.M. Barral, M. Hedvat, P. Diaz, J.C. Reed, J.L. Stebbins, M. Pellecchia, D. Sarkar, and P.B. Fisher Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics J. Cell. Physiol. 226 2011 2484 2493
66. S.Y. Kim, and T.A. Jones The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats Restor. Neurol. Neurosci. 31 2013 87 97
67. S. Laatu, A. Revonsuo, L. Pihko, R. Portin, and J.O. Rinne Visual object recognition deficits in early Parkinson's disease Park. Relat. Disord. 10 2004 227 233
68. T.C. Leung, C.N. Lui, L.W. Chen, W.H. Yung, Y.S. Chan, and K.K. Yung Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats ACS Chem. Neurosci. 3 2012 22 30
69. B.E. Levin, M.M. Llabre, S. Reisman, W.J. Weiner, J. Sanchez-Ramos, C. Singer, and M.C. Brown Visuospatial impairment in Parkinson's disease Neurology 41 1991 365 369
70. J.S. Li, and Y.S. Chao Electrolytic lesions of dorsal CA3 impair episodic-like memory in rats Neurobiol. Learn. Mem. 89 2008 192 198
71. C.L. Lin, Q. Kong, G.D. Cuny, and M.A. Glicksman Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases Future Med. Chem. 4 2012 1689 1700
72. J. Lipski, C.K. Wan, J.Z. Bai, R. Pi, D. Li, and D. Donnelly Neuroprotective potential of ceftriaxone in in vitro models of stroke Neuroscience 146 2007 617 629
73. C.M. Luetjens, N.T. Bui, B. Sengpiel, G. Munstermann, M. Poppe, A.J. Krohn, E. Bauerbach, J. Krieglstein, and J.H. Prehn Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production J. Neurosci. 20 2000 5715 5723
74. S. Mandel, E. Grunblatt, G. Maor, and M.B. Youdim Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray Neurochem. Res. 27 2002 1231 1243
75. J. Mao Glutamate transporter: an unexpected target for some antibiotics Mol. Pain 1 2005 5
76. N.J. Maragakis, J. Dietrich, V. Wong, H. Xue, M. Mayer-Proschel, M.S. Rao, and J.D. Rothstein Glutamate transporter expression and function in human glial progenitors Glia 45 2004 133 143
77. M.J. Marino, O. Valenti, and P.J. Conn Glutamate receptors and Parkinson's disease: opportunities for intervention Drugs Aging 20 2003 377 397
78. W.R. Martin MR spectroscopy in neurodegenerative disease Mol. Imaging Biol. 9 2007 196 203
79. C.K. Meshul, N. Emre, C.M. Nakamura, C. Allen, M.K. Donohue, and J.F. Buckman Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion Neuroscience 88 1999 1 16
80. B.R. Miller, J.L. Dorner, M. Shou, Y. Sari, S.J. Barton, D.R. Sengelaub, R.T. Kennedy, and G.V. Rebec Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse Neuroscience 153 2008 329 337
81. E. Miyoshi, S. Wietzikoski, M. Camplessei, R. Silveira, R.N. Takahashi, and C. Da Cunha Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions Brain Res. Bull. 58 2002 41 47
82. R.E. Moo-Puc, J.L. Gongora-Alfaro, F.J. Alvarez-Cervera, J.C. Pineda, G. Arankowsky-Sandoval, and F. Heredia-Lopez Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy Neuropharmacology 45 2003 493 503
83. R.L. Mosley, E.J. Benner, I. Kadiu, M. Thomas, M.D. Boska, K. Hasan, C. Laurie, and H.E. Gendelman Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease Clin. Neurosci. Res. 6 2006 261 281
84. S.J. Mulligan, and B.A. MacVicar Calcium transients in astrocyte endfeet cause cerebrovascular constrictions Nature 431 2004 195 199
85. D.G. Mumby, A. Tremblay, V. Lecluse, and H. Lehmann Hippocampal damage and anterograde object-recognition in rats after long retention intervals Hippocampus 15 2005 1050 1056
86. R. Nau, H.W. Prange, P. Muth, G. Mahr, S. Menck, H. Kolenda, and F. Sorgel Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges Antimicrob. Agents. Chemother. 37 1993 1518 1524
87. D. Nicholls, and D. Attwell The release and uptake of excitatory amino acids Trends Pharmacol. Sci. 11 1990 462 468
88. M. Nizzardo, M. Nardini, D. Ronchi, S. Salani, C. Donadoni, F. Fortunato, G. Colciago, M. Falcone, C. Simone, G. Riboldi, A. Govoni, N. Bresolin, G.P. Comi, and S. Corti Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms Exp. Neurol. 229 2011 214 225
89. J.P. O'Callaghan, D.B. Miller, and J.F. Reinhard Jr. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Brain Res. 521 1990 73 80
90. Y.B. Ouyang, L.A. Voloboueva, L.J. Xu, and R.G. Giffard Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia J. Neurosci. 27 2007 4253 4260
91. J.L. Perez Velazquez, M.V. Frantseva, and P.L. Carlen In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons J. Neurosci. 17 1997 9085 9094
92. J.C. Perry, D.C. Hipolide, S. Tufik, R.D. Martins, C. Da Cunha, R. Andreatini, and M.A. Vital Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies Exp. Neurol. 195 2005 322 329
93. C. Piekema, R.P. Kessels, R.B. Mars, K.M. Petersson, and G. Fernandez The right hippocampus participates in short-term memory maintenance of object-location associations Neuroimage 33 2006 374 382
94. C. Pittenger, J.H. Krystal, and V. Coric Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder NeuroRx 3 2006 69 81
95. A. Plaitakis, and P. Shashidharan Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease J. Neurol. 247 Suppl. 2 2000 II25 35
96. B. Ramirez-Ruiz, C. Junque, M.J. Marti, F. Valldeoriola, and E. Tolosa Neuropsychological deficits in Parkinson's disease patients with visual hallucinations Mov. Disord. 21 2006 1483 1487
97. W. Robberecht Lack of improvement with ceftriaxone in motoneuron disease Lancet 340 1992 1096 1097
98. S. Robinson, P. Freeman, C. Moore, J.C. Touchon, L. Krentz, and C.K. Meshul Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function Exp. Neurol. 180 2003 74 87
99. M.C. Rodriguez-Oroz, M. Rodriguez, J. Guridi, K. Mewes, V. Chockkman, J. Vitek, M.R. DeLong, and J.A. Obeso The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics Brain 124 2001 1777 1790
100. M.C. Rodriguez, J.A. Obeso, and C.W. Olanow Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection Ann. Neurol. 44 1998 S175 S188
101. U. Roelcke, W. Barnett, E. Wilder-Smith, D. Sigmund, and W. Hacke Untreated neuroborreliosis: Bannwarth's syndrome evolving into acute schizophrenia-like psychosis. A case report J. Neurol. 239 1992 129 131
102. Z.L. Rossetti, and S. Carboni Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory J. Neurosci. 25 2005 2322 2329
103. J.D. Rothstein, M. Dykes-Hoberg, C.A. Pardo, L.A. Bristol, L. Jin, R.W. Kuncl, Y. Kanai, M.A. Hediger, Y. Wang, J.P. Schielke, and D.F. Welty Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate Neuron 16 1996 675 686
104. J.D. Rothstein, S. Patel, M.R. Regan, C. Haenggeli, Y.H. Huang, D.E. Bergles, L. Jin, M. Dykes Hoberg, S. Vidensky, D.S. Chung, S.V. Toan, L.I. Bruijn, Z.Z. Su, P. Gupta, and P.B. Fisher Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature 433 2005 73 77
105. Y. Sari, A.L. Prieto, S.J. Barton, B.R. Miller, and G.V. Rebec Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease J. Biomed. Sci. 17 2010 62
106. N. Schmidt, and B. Ferger Neurochemical findings in the MPTP model of Parkinson's disease J. Neural. Transm. 108 2001 1263 1282
107. J.S. Schneider, J.P. Tinker, M. Van Velson, and M. Giardiniere Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys Brain Res. 860 2000 190 194
108. Y. Smith, A. Charara, and A. Parent Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey J. Comp. Neurol. 364 1996 231 253
109. D. Stanic, D.I. Finkelstein, D.W. Bourke, J. Drago, and M.K. Horne Time course of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat Eur. J. Neurosci. 18 2003 1175 1188
110. A.G. Swennes, L.C. Alworth, S.B. Harvey, C.A. Jones, C.S. King, and S.L. Crowell-Davis Human handling promotes compliant behavior in adult laboratory rabbits J. Am. Assoc. Lab. Anim. Sci. 50 2011 41 45
111. H.N. Sy, S.L. Wu, W.F. Wang, C.H. Chen, Y.T. Huang, Y.M. Liou, C.S. Chiou, C.R. Pawlak, and Y.J. Ho MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus Pharmacol. Biochem. Behav. 95 2010 158 165
112. T. Takano, G.F. Tian, W. Peng, N. Lou, W. Libionka, X. Han, and M. Nedergaard Astrocyte-mediated control of cerebral blood flow Nat. Neurosci. 9 2006 260 267
113. K. Takao, N. Yamasaki, and T. Miyakawa Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders Neurosci. Res. 58 2007 124 132
114. K. Tanaka, K. Watase, T. Manabe, K. Yamada, M. Watanabe, K. Takahashi, H. Iwama, T. Nishikawa, N. Ichihara, T. Kikuchi, S. Okuyama, N. Kawashima, S. Hori, M. Takimoto, and K. Wada Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1 Science 276 1997 1699 1702
115. C. Thone-Reineke, C. Neumann, P. Namsolleck, K. Schmerbach, M. Krikov, J.H. Schefe, K. Lucht, H. Hortnagl, M. Godes, S. Muller, K. Rumschussel, H. Funke-Kaiser, A. Villringer, U.M. Steckelings, and T. Unger The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke J. Hypertens. 26 2008 2426 2435
116. R. Verma, V. Mishra, D. Sasmal, and R. Raghubir Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury Eur. J. Pharmacol. 638 2010 65 71
117. M. Vila, R. Levy, M.T. Herrero, B. Faucheux, J.A. Obeso, Y. Agid, and E.C. Hirsch Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study Neuroscience 71 1996 903 912
118. M.G. Vuckovic, R.I. Wood, D.P. Holschneider, A. Abernathy, D.M. Togasaki, A. Smith, G.M. Petzinger, and M.W. Jakowec Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury Neurobiol. Dis. 32 2008 319 327
119. M. Wada, K. Yoshimi, N. Higo, Y.R. Ren, H. Mochizuki, Y. Mizuno, and S. Kitazawa Statistical parametric mapping of immunopositive cell density Neurosci. Res. 56 2006 96 102
120. H. Wan, J.P. Aggleton, and M.W. Brown Different contributions of the hippocampus and perirhinal cortex to recognition memory J. Neurosci. 19 1999 1142 1148
121. A.L. Wang, Y.M. Liou, C.R. Pawlak, and Y.J. Ho Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats Behav. Brain Res. 208 2010 38 46
122. W.F. Wang, S.L. Wu, Y.M. Liou, A.L. Wang, C.R. Pawlak, and Y.J. Ho MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats Behav. Neurosci. 123 2009 1261 1270
123. P. Willner, and P.J. Mitchell The validity of animal models of predisposition to depression Behav. Pharmacol. 13 2002 169 188
124. M.T. Wong-Riley Cytochrome oxidase: an endogenous metabolic marker for neuronal activity Trends Neurosci. 12 1989 94 101
125. J. Yang, M.X. Li, Y. Luo, T. Chen, J. Liu, P. Fang, B. Jiang, Z.L. Hu, Y. Jin, J.G. Chen, and F. Wang Chronic ceftriaxone treatment rescues hippocampal memory deficit in AQP4 knockout mice via activation of GLT-1 Neuropharmacology 75 2013 213 222
126. W.N. Zhang, H.H. Pothuizen, J. Feldon, and J.N. Rawlins Dissociation of function within the hippocampus: effects of dorsal, ventral and complete excitotoxic hippocampal lesions on spatial navigation Neuroscience 127 2004 289 300
127. M.J. Zigmond, E.D. Abercrombie, T.W. Berger, A.A. Grace, and E.M. Stricker Compensations after lesions of central dopaminergic neurons: some clinical and basic implications Trends Neurosci. 13 1990 290 296
128. S. Zola-Morgan, L.R. Squire, and D.G. Amaral Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus J. Neurosci. 6 1986 2950 2967